[Tolazoline-HCl in cardio-respiratory adaptation of newborns with respiratory distress syndrome (author's transl)].
The pharmacological effects of Tolazoline were studied in newborns with different types of pulmonary diseases. The drug was given when the arterial pO2 remained below 6,65 kP in spite of PEEP, and when the right-to-left shunt was greater than 60%. Continuous monitoring of arterial blood pressure and pO2 were of particular importance. Permanent improvement was found in 50%. Transitional improvement in 30% of the cases and in the remaining 20% the drug had no observable effect.
D001775:Blood Circulation / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D010100:Oxygen / Q000097:blood; D010277:Parasympathomimetics / Q000494:pharmacology / Q000627:therapeutic use; D010313:Partial Pressure; D012119:Respiration / Q000187:drug effects*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*; D013566:Sympathomimetics / Q000494:pharmacology / Q000627:therapeutic use; D014043:Tolazoline / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D010277:Parasympathomimetics; D013566:Sympathomimetics; D014043:Tolazoline; D010100:Oxygen
Die Wirkung von Tolazoline auf die kardiorespiratorische Adaptation bei neugeborenen mit respirationsstörungen.